Response of Topical Capsaicin in Alopecia Areata

Learn more about:
Related Clinical Trial
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata Modified SALT Score for Alopecia Areata Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss – Alopecia Areata TREg Activation in the Treatment of the PELADE (Alopecia Areata) The Effectiveness of Mindfulness Based Cognitive Group Therapy for Social Anxiety Symptoms in People Living With Alopecia Areata Response of Topical Capsaicin in Alopecia Areata Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata. Jaktinib Dihydrochloride Monohydrate in Severe Alopecia Areata Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade Stem Cell Educator Therapy in Alopecia Areata Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata Vytorin in the Treatment of Alopecia Areata Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Efficacy and Safety of LH-8 in Paediatric Alopecia Areata Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Intralesional Steroids in the Treatment of Alopecia Areata A Phase II Study in Patients With Alopecia Areata Topical Crisaborole in Patients With Alopecia Areata Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females Excimer Light for Alopecia Areata Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata Safety and Efficacy Study of SHAPE Gel in Alopecia Areata Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata Topical Garlic Concentrate for Alopecia Areata in Children Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata Aldara for the Treatment of Extensive Alopecia Areata A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata LEO 124249 Ointment in the Treatment of Alopecia Areata Childhood Alopecia Areata Study Using the 308-nm Excimer Laser Alefacept in Patients With Severe Scalp Alopecia Areata Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata

Brief Title

Response of Topical Capsaicin in Alopecia Areata

Official Title

Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin

Brief Summary

      It has been postulated that Alopecia Areata (AA) is, at least in part, a neurologically
      mediated disease. Research supporting this theory includes the finding that nerves
      surrounding the hair follicles are collapsed. We want to take this research a step further
      and show that not only are these perifollicular nerves collapsed, but that their function is
      also impaired.
    

Detailed Description

      To assess the function of perifollicular scalp nerves in AA we will look at the response of
      these nerves to the topical medication capsaicin. Under normal circumstances topical
      capsaicin is known to target nerves in the peripheral nervous system causing short-term
      release of the neuropeptide Substance P (SP) as well as long-term transient depletion of SP.
      We expect the AA patients will respond abnormally to topical capsaicin treatment.
    

Study Phase

Phase 4

Study Type

Interventional


Primary Outcome

Topical capsaicin will quantitatively decrease the amount of Substance P in the scalp of AA patients.

Secondary Outcome

 The scalps of AA patients may be less sensitive to stimuli.

Condition

Alopecia Areata

Intervention

Capsaicin


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

24

Start Date

August 1997

Completion Date

June 2000


Eligibility Criteria

        Inclusion Criteria:

          -  Must have alopecia totalis or universalis.

          -  Be in good health.

          -  Not be taking any medications including topical medications

          -  Be 18 years or older.

          -  Be willing to apply study medication or vehicle as directed, comply with instructions
             and commit to follow-up visits.

          -  Not have had hair chemically treated (including colored hair, permed hair, etc) within
             the month prior to the study.

        Exclusion Criteria:

          -  Absence of extensive alopecia areata.

          -  People not in good health.

          -  People taking medications.

          -  Allergies to capsaicin.

          -  Presence of irritated or visibly inflamed scalp.

          -  Having had hair chemically treated (including colored hair, permed hair, etc.) within
             the month prior to study.
      

Gender

All

Ages

18 Years - 70 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Maria Hordinsky, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00176969

Organization ID

9707M00122


Responsible Party

Sponsor

Study Sponsor

University of Minnesota


Study Sponsor

Maria Hordinsky, MD, Principal Investigator, University of Minnesota


Verification Date

May 2014